Article
Endocrinology & Metabolism
Mark M. Smits, Kristina S. Fluitman, Hilde Herrema, Mark Davids, Mark H. H. Kramer, Albert K. Groen, Clara Belzer, Willem M. de Vos, Djuna L. Cahen, Max Nieuwdorp, Daniel H. van Raalte
Summary: The study aimed to investigate the effects of GLP-1 receptor agonists and DPP-4 inhibitors on the intestinal microbiota in adults with type 2 diabetes. Results showed that these agents did not affect the diversity of the intestinal microbiota, nor were changes in microbial composition related to clinical parameters.
DIABETES & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Shangyu Chai, Ruya Zhang, Ye Zhang, Richard David Carr, Yiman Zheng, Swapnil Rajpathak, Linong Ji
Summary: This meta-analysis summarizes the effects of DPP4 inhibitors on glucagon levels in patients with type 2 diabetes mellitus (T2DM). The results show that DPP4 inhibitors can significantly reduce postprandial glucagon levels in T2DM patients.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Urology & Nephrology
Yang Xu, Edouard L. Fu, Catherine M. Clase, Faizan Mazhar, Meg J. Jardine, Juan J. Carrero
Summary: In this study, it was found that glucagon-like peptide-1 receptor agonists (GLP1RA) were associated with a lower risk of kidney outcomes compared to dipeptidyl peptidase-4 inhibitors (DPP4i). The reductions in both kidney outcomes and major adverse cardiovascular events (MACE) were similar in magnitude to those reported in large cardiovascular outcome trials.
KIDNEY INTERNATIONAL
(2022)
Article
Endocrinology & Metabolism
Signe Stensen, Laerke S. Gasbjerg, Mette M. Rosenkilde, Tina Vilsboll, Jens J. Holst, Bolette Hartmann, Mikkel B. Christensen, Filip K. Knop
Summary: Sitagliptin, a DPP-4 inhibitor, improves glycemic control in type 2 diabetes, and protecting GIP from degradation is essential for its clinical effects.
Article
Medicine, Research & Experimental
Cristina Bouzas, Rosario Pastor, Silvia Garcia, Margalida Monserrat-Mesquida, Miguel Angel Martinez-Gonzalez., Jordi Salas-Salvado, Dolores Corella, Albert Goday, J. Alfredo Martinez, Angel M. Alonso-Gomez, Olga Fernandez-Barcelo, Jesus Vioque, Dora Romaguera, Jose Lopez-Miranda, Ramon Estruch, Francisco J. Tinahones, Jose Lapetra, Lluis Serra-Majema, Blanca Riquelme-Gallegop, Vicente Martin-Sanchez, Xavier Pinto, Miguel Delgado-Rodriguez, Pilar Matia, Josep Vidal, Jersy-Jair Cardenas-Salas, Lidia Daimiel, Emilio Ros, Estefania Toledo, Josep M. Manzanares, Inmaculada Gonzalez-Monge, Miguel-Angel Munoz, Diego Martinez-Urbistondo, Lucas Tojal-Sierra, Carlos Munoz-Bravoaf, Salvador Miralles-Gisbert, Marian Martin, Antonio Garcia-Rios, Sara Castro-Barquero, Jose Carlos Fernandez-Garcia, Jose Manuel Santos-Lozano, F. Javier Basterra-Gortari, Liliana Gutierrez-Carrasquilla, Patricia Guillem-Saiz, Alba Satorres, Itziar Abete, Carolina Sorto-Sanchez, Javier Diez-Espino, Nancy Babio, Montse Fito, Josep A. Tur
Summary: In a one-year study involving 6881 patients with MetS, it was found that those treated with GLP-1RA and DPP-4I had better glycemic profiles, but improvements in weight and waist circumference were modest.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Endocrinology & Metabolism
Natalia McInnes, Stephanie Hall, Irene Hramiak, Ronald J. Sigal, Ronald Goldenberg, Nikhil Gupta, Remi Rabasa-Lhoret, Manoela Braga, Vincent Woo, Farah Sultan, Rose Otto, Ada Smith, Diana Sherifali, Yan Yun Liu, Hertzel C. Gerstein
Summary: The study aimed to evaluate the remission of type 2 diabetes after a short-term intervention using insulin glargine, sitagliptin/metformin, and lifestyle approaches. The results showed that although the primary outcome was not statistically significant, the intervention group had a lower risk of relapse and a higher number of participants remaining in remission in some supplementary analyses.
Article
Endocrinology & Metabolism
Shiau Chin Chong, Norlela Sukor, Sarah Anne Robert, Kim Fong Ng, Nor Azmi Kamaruddin
Summary: This study assessed the impact of endogenous GLP-1 levels on the treatment response to DPP-IV inhibitors in individuals with prediabetes and T2D. The results showed that linagliptin significantly reduced HbA1c and glucose levels in individuals with high GLP-1 levels. This suggests that endogenous GLP-1 levels play an important role in determining the efficacy of DPP-IV inhibitors.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Pharmacology & Pharmacy
Bo Li, Yan Rong Luo, Qian Zhang, Shi Hui Fu, Yun Dai Chen, Jing Wen Tian, Yi Guo
Summary: Sitagliptin significantly reduces atherosclerotic lesion area, suppresses vascular smooth muscle cell apoptosis, and increases the expression of beta-catenin in aortic tissue. In vitro, sitagliptin enhances GLP-1 activity, retards oxidative stress-induced apoptosis, and suppresses the production of inflammatory cytokines.
VASCULAR PHARMACOLOGY
(2021)
Review
Medicine, General & Internal
Carlos Campos, Jeff Unger
Summary: GLP-1RAs and DPP4is are two common classes of medications for the treatment of type 2 diabetes, acting through increasing glucose-dependent insulin secretion and inhibiting peptidase activity, respectively. GLP-1RAs have high glycemic efficacy and weight loss effects, with predominantly transient gastrointestinal adverse events; while DPP4is provide moderate glycemic control but do not offer cardiovascular benefits, with good tolerability.
POSTGRADUATE MEDICINE
(2021)
Review
Chemistry, Medicinal
Anand-Krishna Singh, Dhananjay Yadav, Neha Sharma, Jun-O Jin
Summary: Type 2 diabetes mellitus is characterized by high blood sugar levels, and therapeutic approaches include improving insulin sensitivity and using DPP-IV inhibitors. These inhibitors improve hyperglycemia by stabilizing gut hormones such as glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptides.
Article
Endocrinology & Metabolism
Andrea Kelly, Saba Sheikh, Darko Stefanovski, Amy J. Peleckis, Sarah C. Nyirjesy, Jack N. Eiel, Aniket Sidhaye, Russell Localio, Robert Gallop, Diva D. De Leon, Denis Hadjiliadis, Ronald C. Rubenstein, Michael R. Rickels
Summary: In this study, DPP-4 inhibitor sitagliptin was found to increase meal-related incretin responses, improve early insulin secretion and glucagon suppression in pancreatic insufficient cystic fibrosis (PI-CF) patients with abnormal glucose tolerance. However, there were no significant improvements in glucose tolerance or beta-cell sensitivity to glucose after 6 months of treatment with sitagliptin compared to placebo.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Andrea Kelly, Saba Sheikh, Darko Stefanovski, Amy J. Peleckis, Sarah C. Nyirjesy, Jack N. Eiel, Aniket Sidhaye, Russell Localio, Robert Gallop, Diva D. De Leon, Denis Hadjiliadis, Ronald C. Rubenstein, Michael R. Rickels
Summary: In this study, it was found that the use of sitagliptin in glucose intolerant PI-CF patients increased levels of incretin hormones, improved early insulin secretion and glucagon suppression, but did not affect glucose tolerance or beta-cell sensitivity to glucose.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Review
Endocrinology & Metabolism
Samuel Igweokpala, Naheemot Olaoluwa Sule, Antonios Douros, Oriana H. Y. Yu, Kristian B. Filion
Summary: The use of incretin-based drugs is not associated with the risk of diabetic retinopathy among individuals with type 2 diabetes, according to the synthesis of available evidence from observational studies.
DIABETES OBESITY & METABOLISM
(2023)
Article
Medicine, General & Internal
Hiroshi Nomoto, Sho Furusawa, Akinobu Nakamura, Jun Takeuchi, So Nagai, Hiroki Yokoyama, Ichiro Sakuma, Shinji Taneda, Yoshio Kurihara, Shin Aoki, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Tatsuya Atsumi, Hideaki Miyoshi
Summary: This multicentre trial aims to compare the effects of switching from a DPP-4 inhibitor to oral semaglutide on glycaemic control in patients with T2D. The study will assess the impact of oral semaglutide on HbA1c, body weight, abdominal circumference, blood pressure, and explore the relationship between improvement in metabolic parameters and patient background characteristics, side effects, and other laboratory parameters.
Article
Cardiac & Cardiovascular Systems
Yi-Hsin Chan, Tze-Fan Chao, Shao-Wei Chen, Hsin-Fu Lee, Pei-Ru Li, Wei-Min Chen, Yung-Hsin Yeh, Chi-Tai Kuo, Lai-Chu See, Gregory Y. H. Lip
Summary: The study evaluated the risk of new-onset AF associated with SGLT2i, GLP-1RA, and DPP4i in patients with type 2 diabetes, and found that SGLT2i, but not GLP-1RA, was associated with a lower incidence of AF compared to DPP4i.
CARDIOVASCULAR DIABETOLOGY
(2022)
